News · May 5, 2025

Why is demonstrating bioequivalence essential for generic medicines?

Bioequivalence affects not only treatment quality, but also everyday clinical decisions. With the help of an expert, we explore the scope of the terms and regulations involved.

Article originally published in Intramed, with the participation of our team as a specialized source on the subject.

View full article on Intramed

Back to News

Related news

Jan 21, 2026

ANMAT regulatory update – Bioequivalence/Bioavailability

On 01/20/2026, ANMAT Salud published Disposition 47/2026 in the Official Gazette, updating the list of APIs that must undergo bioequivalence/bioavailability studies.

Read more
Jul 3, 2025

A notable recognition for Dr. Ethel Feleder

Dr. Ethel Feleder, our Director, was selected by ANMAT to join the Network of Experts in Pharmacological Clinical Research.

Read more